Neurophet Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 118

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 31

Neurophet General Information

Description

Developer of a neuroscience simulation software designed to predict and investigate Alzheimer's stimulation effects. The company offers a three-dimensional brain model using magnetic resonance imaging data and a deep learning engine and offers stimulation parameter guidance to concentrate its effect on the target region using numerical optimization techniques, enabling clinicians to predict and visualize the stimulus effect on the brain.

Contact Information

Website
www.neurophet.com
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Samwon Tower 12th Floor
  • 124 Teheran-ro
  • Seoul, Gangnam-gu 06234
  • South Korea
+82
Primary Industry
Decision/Risk Analysis
Vertical(s)
Artificial Intelligence & Machine Learning, TMT, Life Sciences
Corporate Office
  • Samwon Tower 12th Floor
  • 124 Teheran-ro
  • Seoul, Gangnam-gu 06234
  • South Korea
+82

Neurophet Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurophet Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. IPO 27-Aug-2024 Announced Generating Revenue
11. Later Stage VC 29-Feb-2024 Completed Generating Revenue
10. Later Stage VC (Series C) 06-Nov-2023 Completed Startup
9. Accelerator/Incubator 05-Sep-2023 Completed Startup
8. Later Stage VC (Series B) 09-Nov-2021 Completed Startup
7. Later Stage VC (Series A) 30-Jan-2020 Completed Startup
6. Early Stage VC Completed Startup
5. Grant 01-Nov-2017 Completed Startup
4. Accelerator/Incubator 01-Nov-2016 $617K $776K Completed Startup
3. Accelerator/Incubator 01-Jan-2016 $158K Completed Startup
To view Neurophet’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Neurophet Patents

  • 99

    Total Documents Applications and Grants

  • Total Patents Families

  • 70

    Granted

  • 24

    Pending

  • Expiring in next 12 mo

Neurophet Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4358094-A1 Device and method for redesigning treatment prescription according to evaluation of therapeutic effectiveness Pending 31-Aug-2022
EP-4358094-A4 Device and method for redesigning treatment prescription according to evaluation of therapeutic effectiveness Pending 31-Aug-2022
US-20240071589-A1 System and method for redesigning treatment prescriptions according to evaluation of treatment effectiveness Pending 31-Aug-2022
US-11730368-B1 Apparatus and method for providing alzheimer's diagnosis assistance information using mri and pet imaging Active 22-Feb-2022
US-20230263394-A1 Apparatus and method for providing alzheimer's diagnosis assistance information using mri and pet imaging Active 22-Feb-2022 A61B5/0035
To view Neurophet’s complete patent history, request access »

Neurophet Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurophet Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds
Samjin Pharmaceutical Company Corporation Minority
Spacetime Investment Corporate Venture Capital Minority
DB Financial Investment Asset Manager Minority
Mirae Asset Securities Investment Bank Minority
Seoil E&M Corporation Minority
You’re viewing 5 of 31 investors. Get the full list »

Neurophet Investments (1)

Neurophet’s most recent deal was a Joint Venture with Joint venture (Beijing LADO Technology / Neurophet). The deal was made on 30-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint venture (Beijing LADO Technology / Neurophet) 30-Oct-2024 Joint Venture Media and Information Services (B2B)
To view Neurophet’s complete investments history, request access »

Ready to get started?

Request a free trial

Neurophet FAQs

  • When was Neurophet founded?

    Neurophet was founded in 2015.

  • Where is Neurophet headquartered?

    Neurophet is headquartered in Seoul, South Korea.

  • What is the size of Neurophet?

    Neurophet has 118 total employees.

  • What industry is Neurophet in?

    Neurophet’s primary industry is Decision/Risk Analysis.

  • Is Neurophet a private or public company?

    Neurophet is a Private company.

  • What is Neurophet’s current revenue?

    The current revenue for Neurophet is .

  • How much funding has Neurophet raised over time?

    Neurophet has raised $38.7M.

  • Who are Neurophet’s investors?

    Samjin Pharmaceutical Company, Spacetime Investment, DB Financial Investment, Mirae Asset Securities, and Seoil E&M are 5 of 31 investors who have invested in Neurophet.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »